摘要
目的探讨阿托伐他汀对冠心病患者颈动脉粥样硬化的影响,并探讨其疗效及安全性。方法将102例冠心病合并颈动脉粥样硬化患者随机分为阿托伐他汀组(51例)及对照组(51例),分别于给药前和给药1、3、6、12个月后采用高频超声检测颈动脉,记录颈动脉内膜中层厚度(IMT)和粥样硬化斑块面积,并测定其血脂水平。结果治疗组51例患者经阿托伐他汀血清低密度脂蛋白-胆固醇(LDL-c)、TC、TG在治疗1个月后开始下降,高密度脂蛋白-胆固醇(HDL-C)上升,与对照组比较差异有统计学意义(P<0.01),但斑块未见缩小;治疗3个月后,粥样斑块的IMT由(2.23±0.32)mm下降(1.69±0.22)mm,下降幅度为31.94%,与对照组比较差异有统计学意义(P<0.01)。结论阿托伐他汀对冠心病患者的颈动脉粥样硬化斑块具有延缓和稳定作用,对血胆固醇增高的心脑血管病人,及周围大动脉斑块的病人都能获益,从而降低了中风和慢性闭塞性周围动脉硬化,降低了致残率。
Objective To investigate the effect and safety of atorvastatin on the carotid artery artherosclerosis in patients with coronary artery disease.Methods A total of 102 patients with coronary artery disease and carotid artery artherosclerosis diagnosed by coronary angiography and high-frenquency ultrasound were randomized into two groups Atorvastatin group（n=51） and control group（n=51）.High-frenquency ultrasound imaging was used to detect the changes of carotid artery intima media thickness（IMT） and artherosclerosis integral before administration and 12 months after administration,and the levels of blood fat were observed.Results Three months after treatment with Atorvastatin（treated with 20mg）,the levels of TC,TG and LDL-C decreased signifycantly（P〈0.05 or P〈0.01）,while HDL-C increased significantly（P〈0.05）.Three months after treatment with Atorvastatin 20mg,plaque IMT decreased from the（2.23±0.32）mm to（1.69±0.22）mm,for the 31.94% decline,compared with the control group,the IMT was decreased significantly（P〈0.05）,while there was no significant changes in control group（P〉0.05）.Conclusions Atorvastatin is effective in decrease of IMT and the arthemsclerosis integral of cartid artery in patients with coronary artery disease.
出处
《医药论坛杂志》
2011年第16期87-90,共4页
Journal of Medical Forum
